Table.

Patient Demographics and Usage of HCQ

							BCVA
ID	Gender	Age, y	HCQ Indication	Daily Dose, mg/kg	Duration, y	Total Dose, g	OD	OS	Race/Ethnicity
1	F	16	Lyme disease	3.7	0.5	37	20/20; 20/25		Caucasian
2	M	51	Psoriatric arthritis	5.7	9	1314	20/20; 2020		Caucasian
3	F	36	SLE	6.7	10	1460	20/20; 20/20		Caucasian
4 *	F	58	SLE	5.6	20	2798	20/25; 20/25		Caucasian
5	F	33	Sjögren syndrome	6.5	1.5	150	20/20; 20/20		Asian
6	F	53	SLE	1.5	7	256	20/20#		Asian
7	F	56	RA	2.9	0.2	15	20/30#		Caucasian
8	F	33	SLE	3.7	14	1176	20/20#		Hispanic
9	F	48	RA	5.6	6	468	20/20; 20/20		Caucasian
10 *	F	50	SLE	8.9	10	1460	20/25#		Caucasian
11	F	55	SLE	6.5	17	1971	20/20; 20/40		Caucasian
12	F	43	Mixed connective tissue disease	4.4	5	548	20/20; 20/20		Caucasian
13	M	58	Behcet syndrome	4.2	7	511	20/30; 20/25		Asian
14 *	F	48	SLE	7.2	10	1128	20/25#		Asian
15 *	F	50	SLE	4.4	5	730	20/25; 20/25		Caucasian
16 *	F	49	Sjögren syndrome	6.8	12	1752	20/20; 20/20		Caucasian
17	F	44	RA	6.25	10	1068	20/20; 20/20		Caucasian
18	M	23	SLE	4.8	7	1022	20/20; 20/20		Asian
19	F	23	SLE	3.9	1	146	20/20; 20/20		African American
20	F	17	RA	4.2	5	282	20/20; 20/20		Caucasian
21	F	48	Multiple autoimmune syndrome	3.5	2	146	20/20; 20/20		Caucasian
22	F	55	Lyme disease	3	6	438	20/30; 20/50		African American
23	F	10	Sjögren syndrome	7.4	2	146	20/20; 20/20		Hispanic
24	F	53	SLE	4.4	13	1898	20/25; 20/20		Hispanic
25	F	49	RA	5.9	9	1314	20/20; 20/20		Hispanic
26	F	49	SLE	5.1	17	2482	20/20; 20/20		Hispanic
27†	F	73	RA	1.9	26	1460	20/30; 20/25		Caucasian
28†	F	78	SLE	1.9	20	1460	20/25; 20/25		Caucasian
29†	F	64	SLE	5.4	0.5	84	20/20#		Caucasian
30†	F	64	Sjögren syndrome	2.6	2	146	20/20#		African American
31†	F	75	SLE	5.5	3	438	20/25; 20/20		Caucasian

BCVA, best-corrected visual acuity, OD, right eye; OS, left eye; RA, rheumatoid arthritis; SLE, systemic lupus erythematosus.

^*The bold font indicates patients with HCQ toxicity, they are also marked with asterisks.

^†Patient with an intraocular lens.

^#BCVA, best-corrected visual acuity OD.